Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC by Zhenyun Yang, Zhenyun Yang, Zhenyun Yang, Qianyu Wang, Li Hu, Li Hu, Li Hu, Xiaoxian Sima, Xiaoxian Sima, Xiaoxian Sima, Juncheng Wang, Juncheng Wang, Juncheng Wang, Dandan Hu, Dandan Hu, Dandan Hu, Zhongguo Zhou, Zhongguo Zhou, Zhongguo Zhou, Minshan Chen, Minshan Chen, Minshan Chen, Yaojun Zhang, Yaojun Zhang, Yaojun Zhang, Yizhen Fu, Yizhen Fu, Yizhen Fu

Get full text

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study by Zhenyun Yang, Zhenyun Yang, Zhenyun Yang, Weijie Wu, Weijie Wu, Weijie Wu, Zhiwen Hu, Zhiwen Hu, Zhiwen Hu, Yizhen Fu, Yizhen Fu, Yizhen Fu, Zili Hu, Zili Hu, Zili Hu, Yangxun Pan, Yangxun Pan, Yangxun Pan, Juncheng Wang, Juncheng Wang, Juncheng Wang, Jinbin Chen, Jinbin Chen, Jinbin Chen, Zhongguo Zhou, Zhongguo Zhou, Zhongguo Zhou, Yaojun Zhang, Yaojun Zhang, Yaojun Zhang, Minshan Chen, Minshan Chen, Minshan Chen, Dandan Hu, Dandan Hu, Dandan Hu

Get full text

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment by Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen

Get full text